薬局で役立つ経口抗がん薬はじめの一歩

出版社: 羊土社
著者:
発行日: 2020-04-10
分野: 薬学  >  処方/薬局
ISBN: 9784758118736
電子書籍版: 2020-04-10 (第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

3,960 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

商品紹介

薬局薬剤師が困ることの多い,背景にあるレジメン,類似抗がん薬との違いや使い分け,腎障害・肝障害患者の投与量調整,支持療法の目的,注意すべき副作用など,現場で役立つニーズの高いテーマを厳選!

目次

  • 第1章 がん種別 薬物治療の概要
     胃がん
     大腸がん
     肺がん
     乳がん
     前立腺がん
     腎がん
     慢性骨髄性白血病(CML)
     多発性骨髄腫(MM)

    第2章 経口抗がん薬の特徴と使い方
     代謝拮抗薬
      テガフール・ギメラシル・オテラシルカリウム〔ティーエスワン〕
      カペシタビン〔ゼローダ〕
      トリフルリジン・チピラシル〔ロンサーフ〕
      テガフール・ウラシル〔ユーエフティ〕
     分子標的薬
      (1)チロシンキナーゼ阻害薬(EGFR阻害薬)
       ゲフィチニブ〔イレッサ〕
       エルロチニブ〔タルセバ〕
       アファチニブ〔ジオトリフ〕
       オシメルチニブ〔タグリッソ〕
      (2)チロシンキナーゼ阻害薬( EGFR/HER2阻害薬)
       ラパチニブ〔タイケルブ〕
      (3)チロシンキナーゼ阻害薬(ALK阻害薬)
       クリゾチニブ〔ザーコリ〕
       アレクチニブ〔アレセンサ〕
       セリチニブ〔ジカディア〕
       ロルラチニブ〔ローブレナ〕
      (4)チロシンキナーゼ阻害薬(BCR-ABL阻害薬)
       イマチニブ〔グリベック〕
       ニロチニブ〔タシグナ〕
       ダサチニブ〔スプリセル〕
       ボスチニブ〔ボシュリフ〕
       ポナチニブ〔アイクルシグ〕
      (5)マルチキナーゼ阻害薬
       レンバチニブ〔レンビマ〕
       バンデタニブ〔カプレルサ〕
       スニチニブ〔スーテント〕
       ソラフェニブ〔ネクサバール〕
       パゾパニブ〔ヴォトリエント〕
       アキシチニブ〔インライタ〕
       レゴラフェニブ〔スチバーガ〕
      (6)キナーゼ阻害薬(BRAF阻害薬)
       ダブラフェニブ〔タフィンラー〕
      (7)キナーゼ阻害薬(MEK阻害薬)
       トラメチニブ〔メキニスト〕
      (8)mTOR阻害薬
       エベロリムス〔アフィニトール〕
      (9)PARP阻害薬
       オラパリブ〔リムパーザ〕
      (10)CDK4/6阻害薬
       パルボシクリブ〔イブランス〕
       アベマシクリブ〔ベージニオ〕
      (11)プロテアソーム阻害薬
       イキサゾミブ〔ニンラーロ〕
     内分泌療法薬
      (1)抗エストロゲン薬
       タモキシフェン〔ノルバデックス〕/トレミフェン〔フェアストン〕
      (2)アロマターゼ阻害薬
       アナストロゾール〔アリミデックス〕/エキセメスタン〔アロマシン〕/
       レトロゾール〔フェマーラ〕
      (3)抗アンドロゲン薬
       エンザルタミド〔イクスタンジ〕
       ビカルタミド〔カソデックス〕
       アビラテロン〔ザイティガ〕
       ダロルタミド〔ニュベクオ〕
     免疫調節薬(IMiDs)
       サリドマイド〔サレド〕
       レナリドミド〔レブラミド〕
       ポマリドミド〔ポマリスト〕
       コラム:ステロイドに関する諸注意

    第3章 支持療法薬
     1.悪心・嘔吐
     2.発熱性好中球減少症
     3.皮膚障害

    第4章 疼痛緩和治療薬
     1.疼痛緩和治療薬の概要
     2.疼痛緩和治療薬の実際

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 がん種別 薬物治療の概要

P.16 掲載の参考文献
1) 「胃癌治療ガイドライン 医師用2018年1月改訂 第5版」(日本胃癌学会/編), 金原出版, 2018
2) Sasako M, et al:Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29:4387-4393, 2011
3) Bang YJ, et al:Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3 open-label, randomised controlled trial. Lancet, 379:315-321, 2012
4) Fuchs CS, et al:Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 383:31-39, 2014
5) Shitara K, et al:Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer(ABSOLUTE):an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol, 2:277-287, 2017
6) Kang YK, et al:Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390:2461-2471, 2017
P.20 掲載の参考文献
1) 「大腸癌治療ガイドライン 医師用2019年」(大腸癌研究会/編)
2) Andre T, et al:The IDEA(International Duration Evaluation of Adjuvant Chemotherapy) Collaboration:Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX(3 versus 6 months) Regimen for Patients with Stage III Colon Cancer:Trial Design and Current Status. Curr Colorectal Cancer Rep, 9:261-269, 2013
P.23 掲載の参考文献
1) 「肺癌診療ガイドライン2018年版」(日本肺癌学会/編), 金原出版, 2018
2) Douillard JY, et al:Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer:subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol, 5:220-228, 2010
P.26 掲載の参考文献
1) 「乳癌診療ガイドライン2018年版」(日本乳癌学会/編), 金原出版, 2018
2) Davies C, et al:Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial. Lancet, 381:805-816, 2013
3) Goss PE, et al:Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol, 24:355-361, 2013
4) Finn RS, et al:Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med, 375:1925-1936, 2016
5) Sledge GW, et al:MONARCH 2:Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol, 35:2875-2884, 2017
P.28 掲載の参考文献
1) 「前立腺癌診療ガイドライン2016年版」(日本泌尿器科学会/編), メディカルレビュー社, 2016
2) Huggins C, et al:Studies on Prostatic Cancer, I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res, 1:293-297, 1941
3) Labrie F, et al:New hormonal therapy in prostatic carcinoma:combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med, 5:267-275, 1982
4) Tannock IF, et al:TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 351:1502-1512, 2004
5) Scher HI, et al:AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med, 371:421-433, 2014
6) Ryan CJ, et al:Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer(COU-AA-302):final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 16:152-160, 2015
P.30 掲載の参考文献
1) 「腎癌診療ガイドライン2017年版」(日本泌尿器科学会/編), メディカルレビュー社, 2017
2) Escudier B, et al:Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356:125-134, 2007
5) Shariat SF, et al:Words of wisdom. Re:Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ;Global ARCC Trial. N Engl J Med 2007;356:2271-81. Eur Urol, 55:250-252, 2009
6) Rini BI, et al:Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):a randomised phase 3 trial. Lancet, 378:1931-1939, 2011
8) Motzer RJ, et al:Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med, 373:1803-1813, 2015
9) Motzer RJ, et al:Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med, 378:1277-1290, 2018
P.35 掲載の参考文献
1) Hochhaus A, et al:Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase:5-year update of the randomized ENESTnd trial. Leukemia, 30:1044-1054, 2016
2) Cortes JE, et al:Final 5-Year Study Results of DASISION:The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol, 34:2333-2340, 2016
3) Lipton JH, et al:Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia:an international, randomised, open-label, phase 3 trial. Lancet Oncol, 17:612-621, 2016
4) 「造血器腫瘍診療ガイドライン2018年版」(日本血液学会/編), 金原出版, 2018
5) O'Brien SG, et al:Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348:994-1004, 2003
6) Saglio G, et al:Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 362:2251-2259, 2010
7) Kantarjian H, et al:Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med, 362:2260-2270, 2010
8) Apperley JF, et al:Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure:the START a trial. J Clin Oncol, 27:3472-3479, 2009
9) Cortes J, et al:Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109:3207-3213, 2007
10) le Coutre PD, et al:Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance:24-month follow-up results. Leukemia, 26:1189-1194, 2012
11) Giles FJ, et al:Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia, 26:959-962, 2012
12) Gambacorti-Passerini C, et al:Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol, 90:755-768, 2015
13) Cortes JE, et al:A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369:1783-1796, 2013
14) 「血液内科専門医テキスト 改訂第2版」(血液内科学会/編), 南江堂, 2015
15) 「造血器腫瘍診療ガイドライン2018年版」(血液内科学会/編), 金原出版, 2018
P.39 掲載の参考文献
1) 「造血器腫瘍診療ガイドライン2018年版」(日本血液学会/編), 金原出版, 2018
2) 「多発性骨髄腫の診療指針 第4版」(日本骨髄腫学会/編), 文光堂, 2016
3) [NCCN Guidelines Insights:Multiple Myeloma, Version 3. 2018]

第2章 経口抗がん薬の特徴と使い方

P.43 掲載の参考文献
1) Sakuramoto S, et al:Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357:1810-1820, 2007
2) Sasako M, et al:Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29:4387-4393, 2011
3) Koizumi W, et al:S-1 plus cisplatin versus S-1 alone for the first-line treatment of advanced gastric cancer (SPIRITS trial):a phase III trial. Lancet Oncology, 9:215-221, 2008
4) Yoshida K, et al:Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer:Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol, 37:1296-1304, 2019
5) Uesaka K, et al:Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer:a phase 3, open-label, randomised, non-inferiority trial(JASPAC 01). Lancet, 388:248-257, 2016
6) Yamada Y, et al:S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer(TRICOLORE):a randomized, open-label, phase III, noninferiority trial. Ann Oncol, 29:624-631, 2018
7) Okamoto I, et al:Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer:results of a west Japan oncology group study. J Clin Oncol, 28:5240-5246, 2010
P.46 掲載の参考文献
1) 増田啓年,:新規抗悪性腫瘍薬S-1の各配合成分の体内動態(第1報):ラットにおけるS-1単回投与時の各配合成分の吸収および排泄. 薬物動態, 12:289-300, 1997
2) 増田啓年, 他:新規抗悪性腫瘍薬S-1の各配合成分の体内動態(第3報):ラットにおけるS-1反復投与時の各配合成分の吸収, 排泄および肝薬物代謝酵素系に与える影響. 薬物動態, 12:322-331, 1997
P.47 掲載の参考文献
1) Sakuramoto S, et al:Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357:1810-1820, 2007
2) Sasako M, et al:Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29:4387-4393, 2011
3) Uesaka K, et al:Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer:a phase 3, open-label, randomised, non-inferiority trial(JASPAC 01). Lancet, 388:248-257, 2016
P.49 掲載の参考文献
1) Saif MW, et al:An Adverse Interaction Between Warfarin and Fluoropyrimidines Revisited. Clinical Colorectal Cancer, 5:175-180, 2010
2) Giunta G:Warfarin-5-FU interactions. Ann Oncol, 17:176, 2006
P.53 掲載の参考文献
1) Koizumi W, et al:S-1 plus cisplatin versus S-1 alone for the first-line treatment of advanced gastric cancer (SPIRITS trial):a phase III trial. Lancet Oncology, 9:215-221, 2008
2) Yamada Y, et al:Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol, 26:141-148, 2015
3) Yoshida K, et al:Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer:Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol, 37:1296-1304, 2019
4) Yamada Y, et al:Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT):an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol, 14:1278-1286, 2013
5) Yamada Y, et al:S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer(TRICOLORE):a randomized, open-label, phase III, noninferiority trial. Ann Oncol, 29:624-631, 2018
6) Okamoto I, et al:Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer:results of a west Japan oncology group study. J Clin Oncol, 28:5240-5246, 2010
P.55 掲載の参考文献
1) Andre T, et al:Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 27:3109-3116, 2009
2) Twelves C, et al:Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med, 352:2696-2704, 2005
3) Haller DG, et al:Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol, 29:1465-1471, 2011
4) Saltz LB, et al:Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study. J Clin Oncol, 26:2013-2019, 2008
5) ゼローダ(R)医薬品インタビューフォーム
P.56 掲載の参考文献
1) ゼローダ(R)適正使用ガイド(結腸・直腸癌)
P.58 掲載の参考文献
1) ゼローダ(R)適正使用ガイド(結腸・直腸癌)
P.59 掲載の参考文献
1) Miller KK, et al:Chemotherapy-induced hand-foot syndrome and nail changes:a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol, 71:787-794, 2014
2) 平成22年3月厚生労働省, 重篤副作用疾患別対応マニュアル 手足症候群 http://www.info.pmda.go.jp/juutoku/file/jfm1003014.pdf(アクセス日:2020-2-21)
P.61 掲載の参考文献
1) Sawaki A, et al:Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer:a subgroup analysis of the Trastuzumab for Gastric Cancer(ToGA) study. Gastric Cancer, 15:313-322, 2012
1) 「制吐薬適正使用ガイドライン 2015年10月【第2版】一部改訂版 ver.2.2」(日本癌治療学会/編), 2018
2) Doi T, et al:Phase I/II study of capecitabine plus oxaliplatin(XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol, 40:913-920, 2010
3) Geyer CE, et al:Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355:2733-2743, 2006
P.66 掲載の参考文献
1) Mayer RJ, et al:Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med, 372:1909-1919, 2015
2) Shitara K, et al, et al:Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 19,:1437-1448, 2018
P.67 掲載の参考文献
1) ロンサーフについて, 大鵬薬品
P.69 掲載の参考文献
1) ロンサーフ(R)配合錠 添付文書
2) ロンサーフ(R)配合錠 医薬品インタビューフォーム
3) ロンサーフ(R)配合錠 適正使用情報
P.70 掲載の参考文献
1) ロンサーフ(R)配合錠 医薬品インタビューフォーム
2) ロンサーフ(R)配合錠 適正使用情報
P.71 掲載の参考文献
1) ティーエスワン(R)配合OD錠 医薬品インタビューフォーム
1) Yoshino T, et al:Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. Cancer Sci, 107:659-665, 2016
2) ゼローダ(R)錠 医薬品インタビューフォーム
2) Doi T, et al:Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer, 107:429-434, 2012
3) ロンサーフ(R)配合錠 適正使用情報
P.72 掲載の参考文献
1) 「制吐薬適正使用ガイドライン 2015年10月【第2版】一部改訂版 ver.2.2」(日本癌治療学会/編), 2018
2) ロンサーフ(R)配合錠 適正使用情報
P.74 掲載の参考文献
1) Kuboki Y, et al:TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE):an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol, 18:1172-1181, 2017
P.75 掲載の参考文献
1) 藤井節郎, 他:FT-207 および5-FU 誘導体とUracil との同時併用療法に関する研究. 癌と化学療法, 6:377-384, 1979
P.76 掲載の参考文献
1) ユーエフティ(R)の特徴・作用機序. 大鵬薬品工業株式会社ホームページ
P.78 掲載の参考文献
1) Kato H, et al:A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med, 22:1713-1721, 2004
P.80 掲載の参考文献
1) Kato H, et al:A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med, 22:1713-1721, 2004
2) Shirao K, et al:Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur(UFT) plus oral leucovorin(LV) regimen between Japanese and American patients with advanced colorectal cancer:joint United States and Japan study of UFT/LV. J Clin Oncol, 22:3466-3474, 2004
P.81 掲載の参考文献
1) 大山 勝, 他:頭頸部癌におけるUFT腸溶顆粒(E顆粒)とUFTカプセルの副作用に関する比較試験-特に上部消化器系副作用を中心に-. 癌と化学療法, 17:1211-1216, 1990
2) Douillard JY, et al:Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 20:3605-3616, 2002
P.85 掲載の参考文献
1) Wakeling AE, et al:ZD1839(Iressa):an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res, 62:5749-5754, 2002
P.86 掲載の参考文献
1) Fukuoka M, et al:Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS). J Clin Oncol, 29:2866-2874, 2011
2) Rosell R, et al:Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 13:239-246, 2012
3) Inoue A, et al:First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol, 27:1394-1400, 2009
P.87 掲載の参考文献
1) Morihara M, et al:Assessment of gastric acidity of Japanese subjects over the last 15 years. Biol Pharm Bull, 24:313-315, 2001
2) イレッサ(R)錠250 医薬品インタビューフォーム
P.88 掲載の参考文献
1) Park K, et al:Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive nonsmall-cell lung cancer(LUX-Lung 7):a phase 2B, open-label, randomised controlled trial. Lancet Oncol, 17:577-589, 2016
2) Ando M, et al:Predictive factors for interstitial lung disease, antitumor response, and survival in non-smallcell lung cancer patients treated with gefitinib. J Clin Oncol, 24:2549-2556, 2006
3) Saito Y & Gemma A:Current status of DILD in molecular targeted therapies. Int J Clin Oncol, 17:534-541, 2012
P.89 掲載の参考文献
1) イレッサ(R)錠250 医薬品インタビューフォーム
P.91 掲載の参考文献
1) McKillop D, et al:Tumor penetration of gefitinib(Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther, 4:641-649, 2005
2) Petty WJ, et al:Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res, 10:7547-7554, 2004
3) Verweij J, et al:Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib:randomised trial. Lancet, 364:1127-1134, 2004
P.92 掲載の参考文献
1) Camidge DR, et al:Acquired resistance to TKIs in solid tumours:learning from lung cancer. Nat Rev Clin Oncol, 11:473-481, 2014
P.93 掲載の参考文献
1) Katsuya Y, et al:Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer. Cancer Chemother Pharmacol, 76:125-132, 2015
2) Hughes AN, et al:Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol, 27:1220-1226, 2009
P.94 掲載の参考文献
1) 大橋養賢, 他:同一患者におけるGefitinib, Erlotinib 使用時の有害事象発現の比較検討. 癌と化学療法, 36:1327-1331, 2009
1) タルセバ(R)錠 医薬品インタビューフォーム
P.97 掲載の参考文献
1) Park K, et al:Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive nonsmall-cell lung cancer(LUX-Lung 7):a phase 2B, open-label, randomised controlled trial. Lancet Oncol, 17:577-589, 2016
P.98 掲載の参考文献
1) Park K, et al:Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive nonsmall-cell lung cancer(LUX-Lung 7):a phase 2B, open-label, randomised controlled trial. Lancet Oncol, 17:577-589, 2016
P.100 掲載の参考文献
1) Wu YL, et al:Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer:Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clin Lung Cancer, 4:e465-e479, 2018
2) Park K, et al:Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive nonsmall-cell lung cancer(LUX-Lung 7):a phase 2B, open-label, randomised controlled trial. Lancet Oncol, 17:577-589, 2016
3) Schuler M, et al:First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC(LUX-Lung 7):impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol, 145:1569-1579, 2019
P.101 掲載の参考文献
1) Schnell D, et al:Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol, 74:267-275, 2014
2) Wiebe S, et al:Influence of Renal Impairment on the Pharmacokinetics of Afatinib:An Open-Label, Single-Dose Study. Eur J Drug Metab harmacokinet, 42:461-469, 2017
P.102 掲載の参考文献
1) ジオトリフ(R)錠 医薬品インタビューフォームより
2) Wind S, et al:Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig, 34:173-182, 2014
P.104 掲載の参考文献
1) Mok TS, et al:Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med, 376:629-640, 2017
P.105 掲載の参考文献
1) Soria JC, et al:Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 378:113-125, 2018
1) Vishwanathan K, et al:The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients with Non-Small-Cell Lung Cancer and in Healthy Volunteers. J Clin Pharmacol, 58:474-484, 2018
P.107 掲載の参考文献
1) Soria JC, et al:Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 378:113-125, 2018
2) 「肺癌診療ガイドライン2018年版」(日本肺癌学会/編), 金原出版, 2018
P.108 掲載の参考文献
1) タグリッソ(R)錠 医薬品インタビューフォーム
2) Grande E, et al:Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment. J Pharmacol Exp Ther, 369:291-299, 2019
3) Mok TS, et al:Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med, 376:629-640, 2017
P.109 掲載の参考文献
1) Mok TS, et al:Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med, 376:629-640, 2017
2) タグリッソ(R)錠 医薬品インタビューフォーム
P.111 掲載の参考文献
1) Geyer CE, et al:Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355:2733-2743, 2006
2) Johnston S, et al:Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 27:5538-5546, 2009
P.113 掲載の参考文献
1) タイケルブ(R)錠 適正使用ガイド
2) Smith DA, et al:Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol, 67:421-426, 2009
P.114 掲載の参考文献
1) Geyer CE, et al:Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355:2733-2743, 2006
2) Johnston S, et al:Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 27:5538-5546, 2009
P.115 掲載の参考文献
1) タイケルブ(R)錠 適正使用ガイド
1) Geyer CE, et al:Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355:2733-2743, 2006
2) タイケルブ(R)錠 適正使用ガイド
2) Johnston S, et al:Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 27:5538-5546, 2009
P.119 掲載の参考文献
1) 「肺癌患者におけるALK融合遺伝子検査の手引き 第3.1版」(日本肺癌学会), 2019
P.120 掲載の参考文献
1) Solomon BJ, et al:First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med, 371:2167-2177, 2014
P.121 掲載の参考文献
1) Yamazaki S, et al:Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model. Drug Metab Dispos, 43:1417-1429, 2015
P.123 掲載の参考文献
1) Muller IB, et al:Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer:clinical impact of alectinib. Onco Targets Ther, 10:4535-4541, 2017
1) Solomon BJ, et al:First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med, 371:2167-2177, 2014
2) Shimada M, et al:Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction. Onco Targets Ther, 10:3211-3214, 2017
P.125 掲載の参考文献
1) ザーコリ(R)カプセル 医薬品インタビューフォーム
P.127 掲載の参考文献
1) Peters S, et al:Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 377:829-838, 2017
2) Hida T, et al:Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer(J-ALEX):an open-label, randomised phase 3 trial. Lancet, 390:29-39, 2017
P.128 掲載の参考文献
1) Gadgeel S, et al:Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive(ALK+) non-small-cell lung cancer:CNS efficacy results from the ALEX study. Annals of Oncology, 29:2214-2222, 2018
2) 「肺癌診療ガイドライン2018年版」(日本肺癌学会/編), 金原出版, 2018
P.129 掲載の参考文献
1) アレセンサ(R)カプセル 医薬品インタビューフォーム
2) Morcos PN, et al:Clinical Drug-Drug Interactions Through Cytochrome P450 3A(CYP3A) for the Selective ALK Inhibitor Alectinib. Clin Pharmacol Drug Dev, 6:280-291, 2017
P.130 掲載の参考文献
1) Peters S, et al:Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 377:829-838, 2017
P.131 掲載の参考文献
1) Peters S, et al:Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 377:829-838, 2017
P.132 掲載の参考文献
1) アレセンサ(R)カプセル 適正使用ガイド
P.134 掲載の参考文献
1) Shaw AT, et al:Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib(ASCEND-5):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 18:874-886, 2017
1) Cho BC, et al:Efficacy and Safety of Ceritinib(450 mg/day or 600 mg/day) With Food vs 750 mg/day Fasted in Patients With ALK-Positive NSCLC:Primary Efficacy Results From ASCEND-8 Study. J Thorac Oncol, 6. pii:S1556-0864(19)30195-9, 2019
P.136 掲載の参考文献
1) Shaw AT, et al:Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib(ASCEND-5):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 18:874-886, 2017
1) ジカディア(R)カプセル 適正使用ガイド
P.138 掲載の参考文献
1) ジカディア(R)カプセル 医薬品インタビューフォーム
P.140 掲載の参考文献
1) Bayliss R, et al:Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci, 73:1209-1224, 2016
1) Solomon BJ, et al:Lorlatinib in patients with ALK-positive non-small-cell lung cancer:results from a global phase 2 study. Lancet Oncol, 19:1654-1667, 2018
P.141 掲載の参考文献
1) ローブレナ(R)錠 医薬品インタビューフォーム
P.142 掲載の参考文献
1) Solomon BJ, et al:Lorlatinib in patients with ALK-positive non-small-cell lung cancer:results from a global phase 2 study. Lancet Oncol, 19:1654-1667, 2018
P.143 掲載の参考文献
1) ローブレナ(R)錠 医薬品インタビューフォーム
2) National Kidney Foundation:K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification. Am J Kidney Dis, 39:S1-266, 2002
P.145 掲載の参考文献
1) ローブレナ(R)錠 医薬品インタビューフォーム
P.146 掲載の参考文献
1) Deininger M, et al:International randomized study of interferon vs STI571(IRIS)8-year follow-up:sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase(CML-CP)treated with imatinib. Blood, 114:abstract #1126, 2009
2) Hochhaus A, et al:Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med, 376:917-927, 2017
P.147 掲載の参考文献
1) Hochhaus A, et al:Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med, 376:917-927, 2017
P.148 掲載の参考文献
1) ノバルティスファーマの医療関係者向けサイトDR's Net https://drs-net.novartis.co.jp/dr/products/product/glivec/about2/usage/01/
2) 「慢性骨髄性白血病治療の実践マニュアル 改訂版」(European LeukemiaNetコンセンサス日本語版策定委員会/編), エルゼビアジャパン, 2010
P.149 掲載の参考文献
1) 「慢性骨髄性白血病治療の実践マニュアル 改訂版」(European LeukemiaNetコンセンサス日本語版策定委員会/編), エルゼビアジャパン, 2010
2) Tsang J-P, et al. ASCO2006, abstract#6119
3) Feng W, et al. ASCO2006, abstract #6038
4) Cuellar S, et al:BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract, 24:433-452, 2018
P.150 掲載の参考文献
1) Mahon FX, et al:Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years:the prospective, multicentre Stop Imatinib(STIM) trial. Lancet Oncol, 11:1029-1035, 2010
2) Rousselot P, et al:Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol, 32:424-430, 2014
3) Ross DM, et al:Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease:results from the TWISTER study. Blood, 122:515-522, 2013
4) Takahashi N, et al:Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia:the JALSG-STIM213 study. Int J Hematol, 107:185-193, 2018
5) 「造血器腫瘍診療ガイドライン2018年版」(日本血液学会/編), 金原出版, 2018
P.151 掲載の参考文献
1) Morishima Y, et al:Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia:results of a Japanese phase II clinical study. Int J Hematol, 80:261-266, 2004
2) Kanda Y, et al:Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase:does body weight matter? Am J Hematl, 83:835-839, 2008
P.152 掲載の参考文献
1) Pye SM, et al:The effects of imatinib on pregnancy outcome. Blood, 111:5505-5508, 2008
2) Shapira T, et al:How I treat acute and chronic leukemia in pregnancy. Blood Rev, 22:247-259, 2008
3) 「造血器腫瘍診療ガイドライン2018年版」(日本血液学会/編), 金原出版, 2018
P.153 掲載の参考文献
1) グリベック(R)錠 添付文書
2) GLEEVEC(imatinib 米国添付文書)
3) ノバルティスファーマ株式会社:グリベックの副作用マネージメント 支持療法とGrade 評価
4) Deininger MW, et al:Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol, 21:1637-1647, 2003
P.155 掲載の参考文献
1) ノバルティスファーマ株式会社:グリベックの副作用マネージメント 支持療法とGrade 評価
2) O'Brien SG, et al:Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348:994-1004, 2003
3) Talpaz M, et al:Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia:results of a phase 2 study. Blood, 99:1928-1937, 2002
4) Richard T, et al:Four year follow-up of 1027 patients with late chronic phase(L-CP), accelerated phase (AP), or blastic crisis(BC)chronic myeloid leukemia(CML)treated with imatinib in three large phase II trials. Blood, 104:11a, 2004
P.156 掲載の参考文献
1) Saglio G, et al:Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 362:2251-2259, 2010
2) Hochhaus A, et al:Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase:5-year update of the randomized ENESTnd trial. Leukemia, 30:1044-1054, 2016
P.158 掲載の参考文献
1) タシグナ(R)総合製品情報概要
1) Saglio G, et al:Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 362:2251-2259, 2010
P.159 掲載の参考文献
1) 「慢性骨髄性白血病治療の実践マニュアル 改訂版」(European LeukemiaNetコンセンサス日本語版策定委員会/編), エルゼビアジャパン, 2010
1) Saglio G, et al:Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 362:2251-2259, 2010
2) ノバルティスファーマ株式会社:タシグナの副作用マネージメント
3) Rosti G, et al:Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treat Rev, 38:241-248, 2012
4) タシグナ(R)カプセル 添付文書
P.160 掲載の参考文献
1) ノバルティスファーマ株式会社:タシグナの副作用マネージメント
2) 「慢性骨髄性白血病治療の実践マニュアル 改訂版」(European LeukemiaNetコンセンサス日本語版策定委員会/編), エルゼビアジャパン, 2010
3) 「腫瘍循環器ガイド」(堀 正二, 淡田修久/監), メディカルレビュー社, 2018
P.161 掲載の参考文献
1) タシグナ(R)カプセル 添付文書
2) ノバルティスファーマ株式会社:タシグナの副作用マネージメント
P.162 掲載の参考文献
1) タシグナ(R)カプセル 適正使用ガイド
2) Yin OQ, et al:Effects of yogurt and applesauce on the oral bioavailability of nilotinib in healthy volunteers. J Clin Pharmacol, 51:1580-1586, 2011
P.165 掲載の参考文献
1) Saglio G, et al:Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 362:2251-2259, 2010
P.166 掲載の参考文献
1) Kantarjian H, et al:Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med, 362:2260-2270, 2010
P.168 掲載の参考文献
1) Kantarjian H, et al:Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med, 362:2260-2270, 2010
P.170 掲載の参考文献
1) スプリセル(R)錠 添付文書
1) Bergeron A, et al:Lung abnormalities after dasatinib treatment for chronic myeloid leukemia:a case series. Am J Respir Crit Care Med, 176:814-818, 2007
2) Quintas-Cardama A, et al:Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol, 25:3908-3914, 2007
2) スプリセル(R)錠 適正使用ガイド
3) Porkka K, et al:Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer, 116:377-386, 2010
4) スプリセル(R)錠 適正使用ガイド
P.171 掲載の参考文献
1) 「造血器腫瘍診療ガイドライン2018年版」(日本血液学会/編), 金原出版, 2018
2) Hochhaus A, et al:Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase:5-year update of the randomized ENESTnd trial. Leukemia, 30:1044-1054, 2016
3) Cortes JE, et al:Final 5 year study results of DASISION The dasatinib versus imatinib study in treatment naive chronic myeloid leukemia patients trial. JC lin Onco, 34:2333-2340, 2016
4) Shah NP, et al:Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol, 26:3204-3212, 2008
5) Kantarjian HM, et al:Nilotinib(formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 110:3540-3546, 2007
6) 「慢性骨髄性白血病治療の実践マニュアル 改訂版」(European LeukemiaNetコンセンサス日本語版策定委員会/編), エルゼビアジャパン, 2010
P.173 掲載の参考文献
1) Kantarjian H, et al:Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med, 362:2260-2270, 2010
P.174 掲載の参考文献
1) 田原 誠, 他:ボスチニブ水和物(ボシュリフ錠100mg)の薬理学的特徴および臨床試験成績. 日本薬理学雑誌, 147:311-318, 2016
2) Cortes JE, et al:Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia:Results From the Randomized BFORE Trial. J Clin Oncol, 36:231-237, 2018
P.175 掲載の参考文献
1) Cortes JE, et al:Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia:results from the BELA trial. J Clin Oncol, 30:3486-3492, 2012
2) Cortes JE, et al:Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia:Results From the Randomized BFORE Trial. J Clin Oncol, 36:231-237, 2018
3) Mita A, et al:Correlation of plasma concentration and adverse effects of bosutinib:standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Exp Hematol Oncol. 2018 Apr 13;7:9. doi:10.1186/s40164-018-0101-1. eCollection 2018.
P.176 掲載の参考文献
1) Brummendorf TH, et al:Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial. Br J Haematol, 168:69-81, 2015
P.177 掲載の参考文献
1) ボシュリフ(R)錠 適正使用ガイド
P.179 掲載の参考文献
1) ボシュリフ(R)錠 適正使用ガイド
P.181 掲載の参考文献
1) ボシュリフ(R)錠 添付文書
2) Abbas R & Hsyu PH:Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib. Clin Pharmacokinet, 55:1191-1204, 2016
3) ボシュリフ(R)錠 医薬品インタビューフォーム
4) ボシュリフ(R)錠 適正使用ガイド
5) 「臨床・病理 原発性肝癌取扱い規約 第6版補訂版」, 金原出版, 2019
P.182 掲載の参考文献
1) ボシュリフ(R)錠 適正使用ガイド
P.183 掲載の参考文献
1) Cortes JE, et al:Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia:results from the BELA trial. J Clin Oncol, 30:3486-3492, 2012
P.184 掲載の参考文献
1) O'Hare T, et al:Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood, 110:2242-2249, 2007
2) Cortes JE, et al:A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369:1783-1796, 2013
P.185 掲載の参考文献
1) Cortes JE, et al:A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369:1783-1796, 2013
P.186 掲載の参考文献
1) Cortes JE, et al:Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia:final 5-year results of the phase 2 PACE trial. Blood, 132:393-404, 2018
2) Cortes JE, et al:A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369:1783-1796, 2013
P.187 掲載の参考文献
1) Khorana AA, et al:Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 111:4902-4907, 2008
P.188 掲載の参考文献
1) アイクルシグ(R)錠 適正使用ガイド
2) http://www.j-athero.org/publications/gl2017_app.html
3) 「造血器腫瘍診療ガイドライン2018年版」(日本血液学会/編), 金原出版, 2018
P.189 掲載の参考文献
1) アイクルシグ(R)錠 適正使用ガイド
1) アイクルシグ(R)錠 添付文書
2) ICLUSIG(R)(ponatinib 米国添付文書)
P.191 掲載の参考文献
1) Cortes JE, et al:A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369:1783-1796, 2013
P.193 掲載の参考文献
1) Schlumberger M, et al:Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Eng J Med, 372:621-630, 2015
2) Kudo M, et al:Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial. Lancet, 391:1163-1173, 2018
P.195 掲載の参考文献
1) Hong DS, et al:Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res, 21:4801-4810, 2011
2) Kudo M, et al:Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial. Lancet, 391:1163-1173, 2018
3) Clarke JM & Hurwitz HI:Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol, 3:253-263, 2013
P.196 掲載の参考文献
1) Schlumberger M, et al:Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Eng J Med, 372:621-630, 2015
2) Kudo M, et al:Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial. Lancet, 391:1163-1173, 2018
P.198 掲載の参考文献
1) 「チームレンバチニブによる肝細胞癌治療-国立がん研究センター東病院のチーム医療」(池田公史/監, 国立がん研究センター東病院チームレンバチニブ/編), メディカルレビュー社, 2018
1) レンビマ(R)カプセル インタビューフォーム
P.201 掲載の参考文献
1) Wells SA, et al:Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized, double-blind phase III trial. J Clin Oncol, 30:134-141, 2012
P.202 掲載の参考文献
1) Wells SA, et al:Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized, double-blind phase III trial. J Clin Oncol, 30:134-141, 2012
P.203 掲載の参考文献
1) カプレルサ(R)錠100mg 添付文書
1) カプレルサ(R)錠100mg 適正使用ガイド
P.206 掲載の参考文献
1) Demetri GD, et al:Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial. Lancet, 368:1329-1338, 2006
3) Raymond E, et al:Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 364:501-513, 2011
P.207 掲載の参考文献
1) Chow LQ, et al:Sunitinib:from rational design to clinical efficacy. J Clin Oncol, 25:884-896, 2007
2) Hong DS, et al:Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res, 21:4801-4810, 2011
3) Ghoreschi K, et al:Selectivity and therapeutic inhibition of kinases:to be or not to be? Nat Immunol, 10:356-360, 2009
P.208 掲載の参考文献
1) Demetri GD, et al:Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial. Lancet, 368:1329-1338, 2006
3) Raymond E, et al:Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 364:501-513, 2011
P.209 掲載の参考文献
1) スーテント(R)カプセル 添付文書
P.213 掲載の参考文献
1) Escudier B, et al:Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356:125-134, 2007
2) Llovet JM, et al:Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359:378-390, 2008
3) Brose MS, et al:Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial. Lancet, 384:319-328, 2014
P.214 掲載の参考文献
1) Escudier B, et al:Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356:125-134, 2007
2) Llovet JM, et al:Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359:378-390, 2008
3) Brose MS, et al:Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial. Lancet, 384:319-328, 2014
P.215 掲載の参考文献
1) 「肝細胞癌に対するレゴラフェニブ チームレゴラフェニブ-国立がん研究センター東病院のチーム医療」(池田公史/監, 国立がん研究センター東病院チームレゴラフェニブ/編), メディカルレビュー社, 2017
P.216 掲載の参考文献
1) ネクサバール(R)錠 添付文書
P.221 掲載の参考文献
P.223 掲載の参考文献
1) ヴォトリエント錠200mg 医薬品インタビューフォーム
2) van der Graaf WT, et al:Pazopanib for metastatic soft-tissue sarcoma(PALETTE):a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 379:1879-1886, 2012
3) ヴォトリエント(R)錠200mg 適正使用ガイド(悪性軟部腫瘍, 腎細胞癌)
P.224 掲載の参考文献
1) ヴォトリエント錠200mg 医薬品添付文書
2) ヴォトリエント錠200mg 医薬品インタビューフォーム
P.226 掲載の参考文献
1) Rini BI, et al:Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):a randomised phase 3 trial. Lancet, 378:1931-1939, 2011
2)「腎癌診療ガイドライン2017年版」(日本泌尿器科学会/編), メディカルレビュー社, 2017
P.227 掲載の参考文献
1) インライタ錠(R)医薬品インタビューフォーム
P.229 掲載の参考文献
1) Rini BI, et al:Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):a randomised phase 3 trial. Lancet, 378:1931-1939, 2011
2) インライタ(R)錠 適正使用ガイド
P.230 掲載の参考文献
1) インライタ(R)錠1mg, 5mg 医薬品インタビューフォーム
P.231 掲載の参考文献
1) インライタ(R)錠1mg, 5mg 医薬品インタビューフォーム
2) インライタ(R)錠 適正使用ガイド
P.234 掲載の参考文献
1) Grothey A, et al:Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381:303-312, 2013
2) Demetri GD, et al:Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381:295-302, 2013
3) Bruix J, et al:Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 389:56-66, 2017
P.235 掲載の参考文献
1) Grothey A, et al:Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381:303-312, 2013
2) Demetri GD, et al:Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381:295-302, 2013
3) Bruix J, et al:Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 389:56-66, 2017
P.236 掲載の参考文献
1) Wilhelm SM, et al:Regorafenib(BAY 73-4506):a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 129:245-255, 2011
2) Wilhelm SM, et al:BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64:7099-7109, 2004
P.237 掲載の参考文献
1) 「肝細胞癌に対するレゴラフェニブ チームレゴラフェニブ-国立がん研究センター東病院のチーム医療」(池田公史/監, 国立がん研究センター東病院チームレゴラフェニブ/編), メディカルレビュー社, 2017
P.238 掲載の参考文献
1) スチバーガ(R)錠 添付文書
P.241 掲載の参考文献
1) Paik PK, et al:Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol, 29:2046-2051, 2011
2) Pao W & Girard N:New driver mutations in non-small-cell lung cancer. Lancet Oncol, 12:175-180, 2011
P.242 掲載の参考文献
1) 肺癌患者におけるBRAF 遺伝子変異検査の手引き 第1版(日本肺癌学会), 2018
P.243 掲載の参考文献
1) Paik PK, et al:Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol, 29:2046-2051, 2011
2) Planchard D, et al:Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer:an open-label, phase 2 trial. Lancet Oncol, 18:1307-1316, 2017
P.244 掲載の参考文献
1) Ouellet D, et al:Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors. J Pharm Sci, 102:3100-3109, 2013
2) Suttle AB, et al:Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol, 55:392-400, 2015
P.245 掲載の参考文献
1) Planchard D, et al:Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer:an open-label, phase 2 trial. Lancet Oncol, 18:1307-1316, 2017
P.246 掲載の参考文献
1) タフィンラー(R)カプセル 医薬品インタビューフォーム
P.248 掲載の参考文献
1) タフィンラー(R)カプセル 適正使用ガイド
P.250 掲載の参考文献
1) 肺癌患者におけるBRAF 遺伝子変異検査の手引き 第1版(日本肺癌学会), 2018
2) Planchard D, et al:Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer:an open-label, phase 2 trial. Lancet Oncol, 18:1307-1316, 2017
P.251 掲載の参考文献
1) Cox DS, et al:Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-inclass MEK inhibitor, in patients with cancer. J Clin Pharmacol, 53:946-954, 2013
2) メキニスト(R)錠 医薬品インタビューフォーム
P.252 掲載の参考文献
1) メキニスト(R)錠 医薬品インタビューフォーム
P.254 掲載の参考文献
1) メキニスト(R)錠 適正使用ガイド
P.256 掲載の参考文献
2) Yao JC, et al:Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med, 364:514-523, 2011
3) Baselga J, et al:Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med, 366:520-529, 2012
P.257 掲載の参考文献
1) アフィニトール(R)適正使用ガイド
P.258 掲載の参考文献
1) Beck JT, et al:Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2. Breast Cancer Res Treat, 143:459-467, 2014
P.259 掲載の参考文献
1) Sonis ST:A biological approach to mucositis. J Support Oncol, 2:21-32, 2004
P.263 掲載の参考文献
1) Ledermann JA, et al:Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy:an updated analysis from a randomised, placebo-controlled, doubleblind, phase 2 trial. Lancet Oncol, 17:1579-1589, 2016
2) Pujade-Lauraine E, et al:Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21):a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 18:1274-1284, 2017
3) Robson M, et al:Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med, 377:523-533, 2017
4) リムパーザ(R)医薬品インタビューフォーム
P.265 掲載の参考文献
1) リムパーザ(R)錠[卵巣癌]適正使用のためのガイド
2) リムパーザ(R)錠[乳癌]適正使用のためのガイド
P.266 掲載の参考文献
1) リムパーザ(R)錠[卵巣癌]適正使用のためのガイド
2) リムパーザ(R)錠[乳癌]適正使用のためのガイド
P.267 掲載の参考文献
1) Pujade-Lauraine E, et al:Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21):a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 18:1274-1284, 2017
1) Pujade-Lauraine E, et al:Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21):a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 18:1274-1284, 2017
2) Robson M, et al:Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med, 377:523-533, 2017
2) Robson M, et al:Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med, 377:523-533, 2017
P.270 掲載の参考文献
1) Finn RS, et al:Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med, 375:1925-1936, 2016
2) Turner NC, et al:Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med, 373:209-219, 2015
P.272 掲載の参考文献
1) Ruiz-Garcia A, et al:Effect of food on the bioavailability of palbociclib. Cancer Chemother Pharmacol, 79:527-533, 2017
2) Finn RS, et al:Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med, 375:1925-1936, 2016
3) Turner NC et al:Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med, 373:209-219, 2015
4) イブランス(R) カプセル 適正使用ガイド
P.273 掲載の参考文献
1) Finn RS, et al:Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med, 375:1925-1936, 2016
2) Turner NC, et al:Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med, 373:209-219, 2015
P.274 掲載の参考文献
1) Finn RS, et al:Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med, 375:1925-1936, 2016
2) Turner NC, et al:Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med, 373:209-219, 2015
3) イブランス(R)カプセル 適正使用ガイド
P.278 掲載の参考文献
1) Sledge GW Jr, et al:MONARCH 2:Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol, 35:2875-2884, 2017
2) Goetz MP, et al:MONARCH 3:Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol, 35:3638-3646, 2017
3) Johnston S, et al:MONARCH 3 final PFS:a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer, 5:5. doi:10.1038/s41523-018-0097-z, 2019
P.279 掲載の参考文献
1) Finn RS, et al:Palbociclib and letrozole in advanced breast cancer. N Engl J Med, 375:1925-1936, 2016
P.282 掲載の参考文献
1) ベージニオ(R)適正使用ガイド
P.285 掲載の参考文献
1) Sledge GW Jr, et al:MONARCH 2:Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol, 35:2875-2884, 2017
2) Goetz MP, et al:MONARCH 3:Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol, 35:3638-3646, 2017
P.286 掲載の参考文献
1) Moreau P, et al:Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med, 374:1621-1634, 2016
P.287 掲載の参考文献
1) Moreau P, et al:Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med, 374:1621-1634, 2016
P.289 掲載の参考文献
1) Moreau P, et al:Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med, 374:1621-1634, 2016
1) ニンラーロ(R)カプセル副作用アーカイブ胃腸障害(消化器毒性)
2) ニンラーロ(R)カプセル副作用アーカイブ胃腸障害(消化器毒性)
2) ニンラーロ(R)カプセル 適正使用ガイド
P.290 掲載の参考文献
1) ニンラーロ(R)カプセル副作用アーカイブ胃腸障害(消化器毒性)
2) ニンラーロ(R)カプセル 適正使用ガイド
3) NCCN:Clinical Practice Guideline in oncology Antiemesis version1, 2019
P.291 掲載の参考文献
1) ニンラーロ(R)カプセル 適正使用ガイド
1) ニンラーロ(R)カプセル 適正使用ガイド
2) レブラミド(R)カプセル 適正使用ガイド 多発性骨髄腫
P.292 掲載の参考文献
1) ニンラーロ(R)カプセル 適正使用ガイド
1) ニンラーロ(R)カプセル 適正使用ガイド
1) ニンラーロ(R)カプセル 適正使用ガイド
P.295 掲載の参考文献
1) Davies C, et al:Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials. Lancet, 378:771-784, 2011
2) Davies C, et al:Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial. Lancet, 381:805-816, 2013
3) Forward DP, et al:Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer, 90:590-594, 2004
P.296 掲載の参考文献
1) Davies C, et al:Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials. Lancet, 378:771-784, 2011
2) Holli K, et al:Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol, 18:3487-3494, 2000
3) Pagani O, et al:Toremifene and tamoxifen are equally effective for early-stage breast cancer:first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol, 15:1749-1759, 2004
4) Mao C, et al:Toremifene versus tamoxifen for advanced breast cancer. Cochrane Datebase Syst Rev, 11(7):CD008926, 2012
4) Lewis JD, et al:Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer, 116:2307-2315, 2010
5) Zhou WB, et al:Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer:results of four randomized trials. Breast Cancer Res Treat, 128:625-631, 2011
P.297 掲載の参考文献
1) Holli K, et al:Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol, 18:3487-3494, 2000
2) Pagani O, et al:Toremifene and tamoxifen are equally effective for early-stage breast cancer:first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol, 15:1749-1759, 2004
P.298 掲載の参考文献
1) 「乳癌診療ガイドライン」(日本乳癌学会/編), 2018
P.302 掲載の参考文献
1) Howell A, et al:Results of the ATAC(Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365:60-62, 2005
2) Baum M, et al:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer:results of the ATAC(Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer, 98:1802-1810, 2003
3) Forbes JF, et al:Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAC trial. Lancet Oncol, 9:45-53, 2008
4) Dowsett M, et al:Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol, 28:509-518, 2010
5) Mauri D, et al:Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer:meta-analysis. J Natl Cancer Inst, 98:1285-1291, 2006
6) Campos SM, et al:A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer, 9:39-44, 2009
P.304 掲載の参考文献
1) Goss PE & Strasser K:Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol, 19:881-894, 2001
2) Geisler J, et al:In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res, 4:2089-2093, 1998
P.305 掲載の参考文献
1) Howell A, et al:Results of the ATAC(Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365:60-62, 2005
2) Thurlimann B, et al:A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med, 353:2747-2757, 2005
3) Coombes RC, et al:A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med, 350:1081-1092, 2004
P.306 掲載の参考文献
1) Hoegh-Andersen P, et al:Ovariectomized rats as a model of postmenopausal osteoarthritis:validation and application. Arthritis Res Ther, 6:R169-R180, 2004
2) Donnellan PP, et al:Aromatase inhibitors and arthralgia. J Clin Oncol, 19:2767, 2001
P.307 掲載の参考文献
1) アリミデックス(R)錠 インタビューフォーム
2) フェマーラ(R)錠 インタビューフォーム
3) アロマシン(R)錠 インタビューフォーム
P.311 掲載の参考文献
3) Shore ND, et al:Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer(TERRAIN):a randomised, double-blind, phase 2 study. Lancet Oncol, 17:153-163, 2016
4) 「前立腺癌診療ガイドライン2016年版」(日本泌尿器科学会/編), メディカルレビュー社, 2016
P.312 掲載の参考文献
1) イクスタンジ(R)錠40mg, 80mg 医薬品インタビューフォーム
P.313 掲載の参考文献
P.314 掲載の参考文献
1) イクスタンジ(R)錠40mg, 80mg 医薬品添付文書
P.317 掲載の参考文献
1) Akaza H, et al:Combined androgen blockade with bicalutamide for advanced prostate cancer:long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer, 115:3437-3445, 2009
2) Schellhammer PF, et al:Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma:final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology, 50:330-336, 1997
3) 「前立腺癌診療ガイドライン2016年版」(日本泌尿器科学会/編), メディカルレビュー社, 2016
P.319 掲載の参考文献
1) カソデックス(R)錠80mg 医薬品インタビューフォーム
P.322 掲載の参考文献
1) Ryan CJ, et al:Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer(COU-AA-302):final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 16:152-160, 2015
3) Fizazi K, et al:Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med, 377:352-360, 2017
4) 「前立腺癌診療ガイドライン2016年版」(日本泌尿器科学会/編), メディカルレビュー社, 2016
P.323 掲載の参考文献
1) ザイティガ(R)錠250mg 医薬品インタビューフォーム
P.324 掲載の参考文献
P.325 掲載の参考文献
1) ザイティガ(R)錠250mg 医薬品インタビューフォーム
P.328 掲載の参考文献
1) Fizazi K, et al:Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med, 380:1235-1246, 2019
P.329 掲載の参考文献
1) Fizazi K, et al:Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med, 380:1235-1246, 2019
P.330 掲載の参考文献
1) 前田和哉:胆汁排泄とトランスポーター. 日本薬理学雑誌, 135:76-79, 2010
P.333 掲載の参考文献
1) Singhal S, et al:Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341:1565-1571, 1999
2) Barlogie B, et al:Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide:identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98:492-494, 2001
P.334 掲載の参考文献
1) Cavo M, et al:Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study. Lancet, 376:2075-2085, 2010
P.335 掲載の参考文献
1) Singhal S, et al:Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341:1565-1571, 1999
2) Barlogie B, et al:Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide:identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98:492-494, 2001
P.336 掲載の参考文献
1) サレド(R)カプセル 医薬品インタビューフォーム
P.337 掲載の参考文献
1) 「造血器腫瘍診療ガイドライン2018年版」(日本血液学会/編), 金原出版, 2018
2) Rajkumar SV, et al:Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 24:431-436, 2006
3) Weber DM, et al:Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med, 357:2133-2142, 2007
4) Dimopoulos M, et al:Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med, 357:2123-2132, 2007
5) Palumbo A, et al:Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide:a phase III, open-label, randomized trial. J Clin Oncol, 29:986-993, 2011
P.338 掲載の参考文献
1) 「多発性骨髄腫の診療指針 第4版」(日本骨髄腫学会/編), 文光堂, 2016
2) Richardson PG, et al:Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 26:595-608, 2012
3) Delforge M, et al:Treatment-related peripheral neuropathy in multiple myeloma:the challenge continues. Lancet Oncol, 11:1086-1095, 2010
4) Terpos E, et al:European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica, 100:1254-1266, 2015
P.339 掲載の参考文献
1) Chen TL, et al:Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos, 17:402-405, 1989
1) 「多発性骨髄腫の診療指針 第4版」(日本骨髄腫学会/編), 文光堂, 2016
2) Palumbo A & Anderson K:Multiple myeloma. N Engl J Med, 364:1046-1060, 2011
2) Teo SK, et al:Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet, 43:311-327, 2004
3) THALOMID(R)(thalidomide)米国添付文書
P.341 掲載の参考文献
1) レブラミド(R)カプセル 医薬品インタビューフォーム
2) Benboubker L, et al:Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med, 371:906-917, 2014
P.342 掲載の参考文献
1) Rajkumar SV, et al:Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma:an open-label randomised controlled trial. Lancet Oncol, 11:29-37, 2010
2) 「多発性骨髄腫の診療指針 第4版」(日本骨髄腫学会/編), 文光堂, 2016
P.343 掲載の参考文献
1) Benboubker L, et al:Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med, 371:906-917, 2014
P.345 掲載の参考文献
1) Weber DM, et al:Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med, 357:2133-2142, 2007
2) Dimopoulos M, et al:Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med, 357:2123-2132, 2007
3) Dimopoulos MA, et al:Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia, 23:2147-2152, 2009
P.346 掲載の参考文献
1) Benboubker L, et al:Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med, 371:906-917, 2014
2) レブラミド(R)カプセル 医薬品インタビューフォーム
P.347 掲載の参考文献
1) Chen N, et al:Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol, 47:1466-1475, 2007
1) レブラミド(R)カプセル並びにポマリスト(R)カプセルを扱う医療関係者の皆さまへ 2019年2月版, セルジーン株式会社
2) レブラミド(R)カプセル 添付文書
3) Kumar G, et al:Lenalidomide:in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol, 63:1171-1175, 2009
P.355 掲載の参考文献
1) Lopez-Girona A, et al:Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 26:2326-2335, 2012
2) Miguel JS, et al:Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma(MM-003):a randomised, open-label, phase 3 trial. Lancet Oncol, 14:1055-1066, 2013
P.356 掲載の参考文献
1) Miguel JS, et al:Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma(MM-003):a randomised, open-label, phase 3 trial. Lancet Oncol, 14:1055-1066, 2013
2) Dimopoulos MA, et al:Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica, 100:1327-1333, 2015
P.357 掲載の参考文献
1) Miguel JS, et al:Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma(MM-003):a randomised, open-label, phase 3 trial. Lancet Oncol, 14:1055-1066, 2013
2) ポマリスト(R)カプセル 医薬品インタビューフォーム
P.358 掲載の参考文献
1) ポマリスト(R)カプセル 適正使用ガイド
P.359 掲載の参考文献
1) ポマリスト(R)カプセル 適正使用ガイド
P.360 掲載の参考文献
1) ポマリスト(R)カプセル 添付文書
1) レブラミド(R)カプセル並びにポマリスト(R)カプセルを扱う医療関係者の皆さまへ 2019年2月版, セルジーン株式会社
2) POMALYST(R)(pomalidomide)米国添付文書
P.364 掲載の参考文献
1) 「治療薬マニュアル2019」, 医学書院, 2019
2) 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン第3版, 日本肝臓学会, 2019
3) Inaba H & Pui CH:Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol, 2010:1096-1106, 2010

第3章 支持療法薬

P.370 掲載の参考文献
1) 「制吐薬適正使用ガイドライン」2015年10月【第2版】一部改訂版 ver.2.2(2018年10月)」(日本癌治療学会/編), 2018
2) Hashimoto H, et al:Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting(J-FORCE):a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 21:242-249, 2020
P.373 掲載の参考文献
1) 「発熱性好中球減少症(FN)診療ガイドライン 改訂第2版」(日本臨床腫瘍学会/編), 南江堂, 2017
2) 日本癌治療学会:G-CSF 適正使用ガイドライン2013年版ver.5(2018年3月29日公開)
P.377 掲載の参考文献
1) 山本有紀, 他:EGFR 阻害薬に起因する皮膚障害の治療手引き -皮膚科・腫瘍内科有志コンセンサス会議からの提案-. 臨床医薬, 32(12):941-949, 2016
2) Ren Z, et al:Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol, 33:894-900, 2015
3) 白藤宜紀, 他:マルチキナーゼ阻害薬に起因する皮膚障害の治療手引き-皮膚科・腫瘍内科有志コンセンサス会議からの提案-. 臨床医薬, 32(12):951-958, 2016

第4章 疼痛緩和治療薬

P.381 掲載の参考文献
1) 厚生労働省ホームページ https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/gan/gan_kanwa.html
2) WHO の緩和ケアの定義, 日本語定訳:2018年6月緩和ケア関連団体会議作成, 日本緩和医療学会
3) 緩和ケア継続教育プログラムPEACE PROJECT http://www.jspm-peace.jp/data/v3_a/M-2_緩和ケア概論.pdf
4) 「がん疼痛の薬物療法に関するガイドライン2014年版」(緩和医療学会/編), 金原出版, 2014
P.383 掲載の参考文献
1) 「がん疼痛の薬物療法に関するガイドライン2014年版」(緩和医療学会/編), 金原出版, 2014
1) 「がん疼痛の薬物療法に関するガイドライン2014年版」(緩和医療学会/編), 金原出版, 2014
P.384 掲載の参考文献
1) Morita T, et al:Knowledge and beliefs about end-of-life care and the effects of specialized palliative care:a population-based survey in Japan. J Pain Symptom Manage, 31:306-316, 2006
2) Akiyama M, et al:Knowledge, beliefs, and concerns about opioids, palliative care, and homecare of advanced cancer patients:a nationwide survey in Japan. Support Care Cancer, 20:923-931, 2012
3) 「がん疼痛の薬物療法に関するガイドライン2014年版」(緩和医療学会/編), 金原出版, 2014
P.385 掲載の参考文献
1) 厚生労働省医薬・生活衛生局 監視指導・麻薬対策課:医療用麻薬適正使用ガイダンス~がん疼痛及び慢性疼痛治療における医療用麻薬の使用と管理のガイダンス~, 2017
P.386 掲載の参考文献
1) 「がん疼痛の薬物療法に関するガイドライン2014年版」(緩和医療学会/編), 金原出版, 2014
2) 厚生労働省医薬・生活衛生局 監視指導・麻薬対策課:医療用麻薬適正使用ガイダンス~がん疼痛及び慢性疼痛治療における医療用麻薬の使用と管理のガイダンス~, 2017

最近チェックした商品履歴

Loading...